Theravance Biopharma M&A Deal with Zymeworks Inc.
Theravance Biopharma, Inc. completed its merger with Zymeworks Inc., becoming a wholly owned subsidiary of Zymeworks. Shareholders received $17.00 in cash per share plus one contingent value right (CVR) per share. The transaction was finalized on September 23, 2026, following the original merger agreement signed in June 2026.
- Counterparty
- Zymeworks Inc.